Anti-oxidative or anti-inflammatory additives reduce ischemia/reperfusions injury in an animal model of cardiopulmonary bypass
| Autor: | Johannes Seeger, Marie Mewes, Sophie Sigusch, Aida Salameh, Ingo Dähnert, Marcel Vollroth, Stefan Dhein, Philipp Kiefer |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0106 biological sciences
0301 basic medicine Cardiac output Hemodynamics Minocycline EGCG ischemia/reperfusion injury 01 natural sciences law.invention DNA deoxyribonucleic acid law ACT activated clotting time cC3 cleaved caspase-3 lcsh:QH301-705.5 NT nitrotyrosine Ejection fraction Heart TNFα tumor necrosis factor α PAR poly-ADP-ribose Cardiology EGCG epigallo-3-catechin-gallate medicine.symptom General Agricultural and Biological Sciences PARP poly-ADP-ribose polymerase medicine.drug HIF1α hypoxia-inducible factor α medicine.medical_specialty CO cardiac output Ischemia Cardio-pulmonary bypass Article HPLC high pressure liquid chromatography MPTP mitochondrial permeability transition pore 03 medical and health sciences ROS reactive oxygen species Internal medicine Cardiopulmonary bypass medicine EF ejection fraction business.industry Hypoxia (medical) medicine.disease AEC 3-amino-9-ethylcarbazole AIF apoptosis-inducing factor 030104 developmental biology lcsh:Biology (General) CPB cardio-pulmonary bypass business Reperfusion injury 010606 plant biology & botany |
| Zdroj: | Saudi Journal of Biological Sciences, Vol 27, Iss 1, Pp 18-29 (2020) Saudi Journal of Biological Sciences |
| ISSN: | 1319-562X |
| Popis: | Severe inborn cardiac malformations are typically corrected in cardioplegia, with a cardio-pulmonary bypass (CPB) taking over body circulation. During the operation the arrested hearts are subjected to a global ischemia/reperfusion injury. Although the applied cardioplegic solutions have a certain protective effect, application of additional substances to reduce cardiac damage are of interest.18 domestic piglets (10–15 kg) were subjected to a 90 min CPB and a 120 min reperfusion phase without or with the application of epigallocatechin-3-gallate (10 mg/kg body weight) or minocycline (4 mg/kg body weight), with both drugs given before and after CPB. 18 additional sham-operated piglets without or with epigallocatechin-3-gallate or minocycline served as controls. In total 36 piglets were analyzed (3 CPB-groups and 3 control groups without or with epigallocatechin-3-gallate or minocycline respectively; 6 piglets per group). Hemodynamic and blood parameters and ATP-measurements were assessed. Moreover, a histological evaluation of the heart muscle was performed. Results: Piglets of the CPB-group needed more catecholamine support to achieve sufficient blood pressure. Ejection fraction and cardiac output were not different between the 6 groups. However, cardiac ATP-levels and blood lactate were significantly lower and creatine kinase was significantly higher in the three CPB-groups. Markers of apoptosis, hypoxia, nitrosative and oxidative stress were significantly elevated in hearts of the CPB-group. Nevertheless, addition of epigallocatechin-3-gallate or minocycline significantly reduced markers of myocardial damage. Noteworthy, EGCG was more effective in reducing markers of hypoxia, whereas minocycline more efficiently decreased inflammation. Conclusions: While epigallocatechin-3-gallate or minocycline did not improve cardiac hemodynamics, markers of myocardial damage were significantly lower in the CPB-groups with epigallocatechin-3-gallate or minocycline supplementation. Keywords: Cardio-pulmonary bypass, Heart, Minocycline, EGCG, ischemia/reperfusion injury |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|